These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 24493489)

  • 1. Canagliflozin.
    Keller DL
    Cleve Clin J Med; 2014 Feb; 81(2):88-90. PubMed ID: 24493489
    [No Abstract]   [Full Text] [Related]  

  • 2. Canagliflozin.
    Rodríguez-Gutiérrez R; Gonzalez-Saldivar G
    Cleve Clin J Med; 2014 Feb; 81(2):87-8. PubMed ID: 24493488
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug approved for type 2 diabetes.
    Nurs Times; 2014 Jul 2-8; 110(27):4. PubMed ID: 25095559
    [No Abstract]   [Full Text] [Related]  

  • 4. Treating type 2 diabetes with canagliflozin.
    Van Gilder D; Jungemann S
    S D Med; 2013 Jul; 66(7):280-1. PubMed ID: 23957114
    [No Abstract]   [Full Text] [Related]  

  • 5. Canagliflozin: a new drug for type 2.
    Goldman-Levine J
    Diabetes Self Manag; 2013; 30(4):30, 32. PubMed ID: 23961597
    [No Abstract]   [Full Text] [Related]  

  • 6. [Canagliflozin. For treating diabetes].
    Sabourin G
    Perspect Infirm; 2013; 10(3):59. PubMed ID: 23705284
    [No Abstract]   [Full Text] [Related]  

  • 7. Canagliflozin, alogliptin benzoate, and ospemifene.
    Hussar DA; Frimpong JO
    J Am Pharm Assoc (2003); 2013; 53(4):442-7. PubMed ID: 23892821
    [No Abstract]   [Full Text] [Related]  

  • 8. US approves "new class" of diabetes drug, under review in Canada.
    Lange-Chenier H
    CMAJ; 2013 Jul; 185(10):E470. PubMed ID: 23734031
    [No Abstract]   [Full Text] [Related]  

  • 9. Canagliflozin for the treatment of type 2 diabetes.
    Babu A
    Drugs Today (Barc); 2013 Jun; 49(6):363-76. PubMed ID: 23807940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canagliflozin: Improving diabetes by making urine sweet.
    Vouyiouklis M
    Cleve Clin J Med; 2013 Nov; 80(11):683-7. PubMed ID: 24186885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
    Usiskin K; Kline I; Fung A; Mayer C; Meininger G
    Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
    Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In reply.
    Vouyiouklis M
    Cleve Clin J Med; 2014 Feb; 81(2):90. PubMed ID: 24493490
    [No Abstract]   [Full Text] [Related]  

  • 14. [Canagliflozin (Invokana): kidney SGLT2 cotransporter inhibitor for treating type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2014 Dec; 69(12):692-9. PubMed ID: 25796788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
    Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
    Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Nyirjesy P; Zhao Y; Ways K; Usiskin K
    Curr Med Res Opin; 2012 Jul; 28(7):1173-8. PubMed ID: 22632452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
    Stein P; Berg JK; Morrow L; Polidori D; Artis E; Rusch S; Vaccaro N; Devineni D
    Metabolism; 2014 Oct; 63(10):1296-303. PubMed ID: 25110280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
    Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
    Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel approach.
    Gebel E
    Diabetes Forecast; 2013 Jun; 66(6):32-4. PubMed ID: 23802291
    [No Abstract]   [Full Text] [Related]  

  • 20. Canaglifozin (Invokana) for type 2 diabetes.
    Med Lett Drugs Ther; 2013 May; 55(1416):37-9. PubMed ID: 23669782
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.